[1]柴 静,张家弘,李梦雪.子宫内膜癌组织中TMIGD2，TIGIT 的表达及其与临床病理特征的相关性研究[J].现代检验医学杂志,2023,38(06):87-91+158.[doi:10.3969/j.issn.1671-7414.2023.06.016]
　CHAI Jing,ZHANG Jiahong,LI Mengxue.Expression of TMIGD2 and TIGIT in Endometrial Cancer Tissue and Their Correlation with Clinical Pathological Features[J].Journal of Modern Laboratory Medicine,2023,38(06):87-91+158.[doi:10.3969/j.issn.1671-7414.2023.06.016]
点击复制

子宫内膜癌组织中TMIGD2，TIGIT 的表达及其与临床病理特征的相关性研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第38卷
期数:
2023年06期
页码:
87-91+158
栏目:
论著
出版日期:
2023-11-15

文章信息/Info

Title:
Expression of TMIGD2 and TIGIT in Endometrial Cancer Tissue and Their Correlation with Clinical Pathological Features
文章编号:
1671-7414（2023）06-087-06
作者:
柴 静; 张家弘; 李梦雪
（唐山市妇幼保健院妇科，河北唐山 063000）
Author(s):
CHAI Jing; ZHANG Jiahong; LI Mengxue
（Department of Gynecology, Tangshan Maternal and Child Health Hospital, Hebei Tangshan 063000, China）
关键词:
子宫内膜癌; 跨膜和免疫球蛋白结构域2(TMIGD2); T 细胞免疫球蛋白和免疫受体酪氨酸抑制基序结构域(TIGIT)
分类号:
R737.33；R730.43
DOI:
10.3969/j.issn.1671-7414.2023.06.016
文献标志码:
A
摘要:
目的 探究子宫内膜癌(endometrial cancinoma) 组织中跨膜和免疫球蛋白结构域2（transmembrane andimmunoglobulin domain containing 2，TMIGD2），T 细胞免疫球蛋白和免疫受体酪氨酸抑制基序结构域（T cellimmunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain，TIGIT）的表达及其与临床病理特征的相关性。方法 选取2016 年1 月～ 2018 年1 月唐山市妇幼保健院诊治的160 例子宫内膜癌患者为研究对象，收集患者术中切除的癌组织及癌旁正常组织。采用免疫组织化学法检测TMIGD2 和TIGIT 表达；对子宫内膜癌组织TMIGD2 与TIGIT表达的相关性进行Spearman 法分析；采用Kaplan-Meier 法分析子宫内膜癌组织TMIGD2，TIGIT 表达与患者预后的关系；影响子宫内膜癌患者预后的因素采用COX 回归分析。结果 子宫内膜癌组织中TMIGD2 和TIGIT 高表达率分别为67.50%，72.50%，均高于癌旁正常组织的21.25%，17.50%，差异具有统计学意义（χ2=69.327，97.778，均P ＜ 0.01）。子宫内膜癌组织中TMIGD2 与TIGIT 表达呈正相关(r=0.422，P<0.001)；TMIGD2，TIGIT 表达水平均与FIGO 分期、淋巴结转移、肌层浸润程度有关（χ2=6.565 ～ 20.323，均P ＜ 0.05）；TMIGD2，TIGIT 低表达组患者生存率分别为82.69%，86.36%，均高于高表达组的38.89%，40.52%，差异具有统计学意义（χ2=27.045，26.925，均P ＜ 0.05）。COX回归分析发现FIGO 分期高（HR=2.716，P=0.04）、TMIGD2 高表达（HR=1.314，P=0.02）、TIGIT 高表达（HR=4.303，P ＜ 0.01）是子宫内膜癌患者预后的危险因素。结论 子宫内膜癌组织中TMIGD2 和TIGIT 均高表达，均与临床病理特征及预后有密切联系。
Abstract:
Objective To explore the expression of transmembrane and immunoglobulin domain containing 2 (TMIGD2), T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif (TIGIT) in endometrial carcinoma and their correlation with clinicopathological characteristics. Methods A total of 160 patients with endometrial cancer who were treated in Tangshan Maternal and Child Health Hospital from January 2016 to January 2018 were regarded as the study subjects, and the cancer tissues and normal tissues adjacent to the cancer were collected. The expression of TMIGD2 and TIGIT was detected by immunohistochemistry，the correlation between TMIGD2 and TIGIT expression in endometrial carcinoma was analyzed by Spearman method. Kaplan-Meier method was applied to analyze the relationship between the expression of TMIGD2 and TIGIT in endometrial carcinoma and the prognosis of patients; and the factors affecting the prognosis of endometrial cancer patients were analyzed by COX regression. Results The higher expression rates of TMIGD2 and TIGIT in endometrial cancer tissue were 67.50% and 72.50%, respectively, which were higher than those in adjacent normal tissues by 21.25% and 17.50%, with statistically significant differences (χ2=69.327，97.778，all P<0.01)．The expression of TMIGD2 and TIGIT in endometrial cancer tissue was positively correlated (r=0.422, P<0.001)．The expression levels of TMIGD2 and TIGIT were all related to FIGO staging, lymph node metastasis, and degree of muscle infiltration (χ2=6.565 ～ 20.323, all P<0.05). The survival rates of patients in the low expression group of TMIGD2 and TIGIT were 82.69% and 86.36%, respectively，which were higher than those in the high expression group of 38.89% and 40.52%，and the differences were statistically significant (χ2=27.045, 26.925,all P<0.05) ．COX regression analysis found that high FIGO stage (HR=2.716, P=0.04), high expression of TMIGD2 (HR=1.314, P=0.02), high expression of TIGIT (HR=4.303, P ＜ 0.01) were risk factors for the prognosis of endometrial cancer patients. Conclusion TMIGD2 and TIGIT were highly expressed in endometrial carcinoma, which were closely related to clinicopathological characteristics and prognosis.

参考文献/References:

[1] URICK M E, BELL D W. Clinical actionability of molecular targets in endometrial cancer[J]. Nature Reviews Cancer, 2019, 19(9): 510-521.
[2] 李晓妍, 高秀娟, 刘雪洁. miRNA-34b 对子宫内膜癌细胞凋亡、侵袭、迁移的影响及作用机制[J]. 现代检验医学杂志, 2022, 37(6): 88-93, 98. LI Xiaoyan, GAO Xiujuan, LIU Xuejie. Effect and mechanism of miR-34b on apoptosis, invasion and migration of endometrial cancer cells[J]. Journal of Modern Laboratory Medicine, 2022, 37(6): 88-93, 98.
[3] BIMBATTI D, CAVASIN N, GALUPPINI F, et al. Liver metastases of unknown primary renal cell carcinoma treated with immune checkpoint inhibitors plus tyrosine kinase inhibitors: a case report and literature review[J]. Anticancer Research, 2023,43(5):2359-2365.
[4] 黄玉斌, 刘霄, 徐翠香, 等. 中晚期恶性肿瘤患者应用PD-1 抑制剂多周期治疗对外周血淋巴细胞亚群影响的动态变化研究[J]. 现代检验医学杂志, 2022,37(2): 23-27. HUANG Yubin, LIU Xiao, XU Cuixiang, et al. Study on the dynamic changes of the effect of PD-1 inhibitor multi-cycle therapy on peripheral blood lymphocyte subsets in patients with advanced malignant tumors[J].Journal of Modern Laboratory Medicine, 2022, 37(2):23-27.
[5] 穆业腾, 郭冲, 胡楠楠, 等. 免疫检查点TIGIT 慢病毒表达载体的构建和稳定表达TIGIT 细胞系的建立[J]. 吉林大学学报( 医学版), 2022, 48(5): 1341-1347. MU Yeteng, GUO Chong, HU Nannan, et al. Construction of immune checkpoint TIGIT lentivirus expression vector and establishment of cell line stably expressing TIGIT[J]. Journal of Jilin University(Medicine Edition), 2022, 48(5): 1341-1347.
[6] XIAO Yao, LI Hao, YANG Leilei, et al. The expression patterns and associated clinical parameters of human endogenous retrovirus-H long terminal repeat-associating protein 2 and transmembrane and immunoglobulin domain containing 2 in oral squamous cell carcinoma[J]. Disease Markers, 2019, 2019:5421985.
[7] 卢惠, 王华芳. 免疫检查点分子TIGIT 在血液恶性肿瘤中的研究进展[J]. 中国实验血液学杂志, 2021,29(3): 993-997. LU Hui, WANG Huafang. Research advance of immune checkpoint molecule TIGIT in hematological malignancies-review[J]. Journal of Experimental Hematology, 2021, 29(3): 993-997.
[8] PECORELLI S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium[J]. International Journal of Gynecology and Obstetrics, 2009,105(2):103-104.
[9] ERDEMOGLU E, SEREL T A, KARACAN E, et al. Artificial intelligence for prediction of endometrial intraepithelial neoplasia and endometrial cancer risks in pre- and postmenopausal women[J]. AJOG Global Reports, 2023, 3(1):100154.
[10] 陈晓宇, 曾庆维, 陈红林, 等. 子宫内膜癌组织中miR-3188 和mTOR 表达量与预后的相关性研究[J].现代检验医学杂志, 2021, 36(6): 17-21. CHEN Xiaoyu, ZENG Qingwei, CHEN Honglin, et al. Study on the correlation between the expression levels of miR-3188 and mTOR in endometrial cancer and the prognosis[J]. Journal of Modern Laboratory Medicine,2021, 36(6): 17-21.
[11] 张岩, 江路, 燕鑫. 子宫内膜癌免疫检查点阻断治疗的进展[J]. 中国医刊, 2021, 56(8): 833-836. ZHANG Yan, JIANG Lu, YAN Xin. Progress of immune checkpoint blocking therapy in endometrial cancer[J]. Chinese Journal of Medicine, 2021, 56(8):833-836.
[12] GREEN A K, FEINBERG J, MAKKER V. A review of immune checkpoint blockade therapy in endometrial cancer[J]. American Society of Clinical Oncology Educational Book, 2020, 40: 1-7.
[13] ZONG Liju, MO Shengwei, SUN Zezheng, et al. Analysis of the immune checkpoint V-domain Igcontaining suppressor of T-cell activation (VISTA) in endometrial cancer[J]. Modern Pathology, 2022, 35(2):266-273.
[14] ZHANG Yubo, YANG Ruiye, XU Chunyu, et al. Analysis of the immune checkpoint lymphocyte activation gene-3 (LAG-3) in endometrial cancer:an emerging target for immunotherapy[J]. Pathology Research and Practice, 2022, 236: 153990.
[15] 刘思思, 冯文. PD-1/PD-L1 信号通路在子宫内膜癌中的研究进展[J]. 现代肿瘤医学, 2020, 28(10):1786-1789. LIU Sisi, FENG Wen. Progress in the study of PD-1/PD-L1 signaling pathway in endometrial cancer[J].Journal of Modern Oncology, 2020, 28(10): 1786-1789.
[16] 谢瑞华, 季红莉, 付万发. 结直肠癌组织HHLA2,TMIGD2 表达及其临床病理意义[J]. 胃肠病学和肝病学杂志, 2021, 30(4): 391-395. XIE Ruihua, JI Hongli, FU Wanfa. Expression and clinicopathological significance of HHLA2 and TMIGD2 in colorectal cancer tissues[J]. Chinese Journal of Gastroenterology and Hepatology, 2021,30(4): 391-395.
[17] CHAUVIN J M, ZAROUR H M. TIGIT in cancer immunotherapy[J]. Journal for Immunotherapy of Cancer, 2020, 8(2): e000957.
[18] GUO Hui, ZHANG Cheng, TANG Xiaotong, et al. HHLA2 activates the JAK/STAT signaling pathway by binding to TMIGD2 in hepatocellular carcinoma cells[J]. Inflammation, 2022, 45(4): 1585-1599.
[19] 符圆圆, 郑盼盼, 孔彩霞, 等. HHLA2 及其受体TMIGD2 在卵巢癌组织中的表达及其临床意义[J].中国肿瘤生物治疗杂志, 2022, 29(9): 822-827. FU Yuanyuan, ZHENG Panpan, KONG Caixia, et al. Expression characteristics and clinical significance of HHLA2 and its receptor TMIGD2 in ovarian cancer tissues[J]. Chinese Journal of Cancer Biotherapy, 2022, 29(9): 822-827.
[20] WU Lei, MAO Liang, LIU Jianfeng, et al. Blockade of TIGIT/CD155 signaling reverses T-cell exhaustion and enhances antitumor capability in head and neck squamous cell carcinoma[J]. Cancer Immunology Research, 2019, 7(10): 1700-1713.
[21] 吴洁琼, 任敦强, 毕焕焕, 等. 免疫检查点TIGIT在肺癌免疫治疗中的研究进展[J]. 中国肺癌杂志,2022, 25(11): 819-827. WU Jieqiong, REN Dunqiang, BI Huanhuan, et al. Research progress of immune checkpoint TIGIT in lung cancer immunotherapy[J]. Chinese Journal of Lung Cancer, 2022, 25(11): 819-827.

相似文献/References:

[1]李 玲a,罗雅文a,何 霞a,等.子宫内膜癌患者BMI与血清HE4,CA125联合检测的诊断价值[J].现代检验医学杂志,2018,33(05):91.[doi:10.3969/j.issn.1671-7414.2018.05.024]
　LI Linga,LUO Ya-wena,HE Xiaa,et al.Diagnostic Value of Combined Detection of Body Mass Index and Serum HE4,CA125 in Patients with Endometrial Carcinoma[J].Journal of Modern Laboratory Medicine,2018,33(06):91.[doi:10.3969/j.issn.1671-7414.2018.05.024]
[2]李晓丽,胡陇娟.子宫内膜癌组织中长链非编码RNA ZEB1-AS1的表达与临床特征及对化疗药物耐药性研究[J].现代检验医学杂志,2019,34(04):35.[doi:10.3969/j.issn.1671-7414.2019.04.009]
　LI Xiao-li,HU Long-juan.Research on Expression and Clinical Characteristics of Long-Chain Non-Coding RNA ZEB1-AS1 in Endometrial Carcinoma and Resistance to Chemotherapy Drugs[J].Journal of Modern Laboratory Medicine,2019,34(06):35.[doi:10.3969/j.issn.1671-7414.2019.04.009]
[3]王娟,刘鑫,席稳燕.HMMR-AS1 在子宫内膜癌化疗耐药中的作用[J].现代检验医学杂志,2020,35(05):45.[doi:10.3969/j.issn.1671-7414.2020.05.012]
　WANG Juan,LIU Xin,XI Wen-yan.Effect of HMMR-AS1 on the Chemotherapy-Resistance of Endometrial Cancer[J].Journal of Modern Laboratory Medicine,2020,35(06):45.[doi:10.3969/j.issn.1671-7414.2020.05.012]
[4]李功娟,张治洋,樊阳阳.FEZF1-AS1在子宫内膜癌中的表达及其与患者临床特征的相关性[J].现代检验医学杂志,2021,36(01):77.[doi:10.3969/j.issn.1671-7414.2021.01.020]
　LI Gong-juan,ZHANG Zhi-yang,FAN Yang-yang.Expression of FEZF1-AS1 in Endometrial Carcinoma and Its Correlation with Clinical Characteristics of Patients[J].Journal of Modern Laboratory Medicine,2021,36(06):77.[doi:10.3969/j.issn.1671-7414.2021.01.020]
[5]陈丽华,朱婕曼,刘玉凤,等.子宫内膜癌组织中血管紧张素~1-7及线粒体组装受体水平表达与临床病理特征的相关性[J].现代检验医学杂志,2021,36(02):24.[doi:doi:10.3969/j.issn.1671-7414.2021.02.006]
　CHEN Li-hua,ZHU Jie-man,LIU Yu-feng,et al.Correlation between the Expression of Angiotensin (1-7) and Mitochondrial Assembled Receptors and Clinicopathological Characteristics in Endometrial Cancer[J].Journal of Modern Laboratory Medicine,2021,36(06):24.[doi:doi:10.3969/j.issn.1671-7414.2021.02.006]
[6]陈晓宇,曾庆维,陈红林,等.子宫内膜癌组织中miR-3188和mTOR表达量与预后的相关性研究[J].现代检验医学杂志,2021,36(06):17.[doi:10.3969/j.issn.1671-7414.2021.06.004]
　CHEN Xiao-yu,ZENG Qing-wei,CHEN Hong-lin,et al.Study on the Correlation between the Expression Levels of miR-3188 and mTOR in Endometrial Cancer and the Prognosis[J].Journal of Modern Laboratory Medicine,2021,36(06):17.[doi:10.3969/j.issn.1671-7414.2021.06.004]
[7]刘静雅,张海亮,李宝平,等.长链非编码 RNA SNHG1在子宫内膜癌中的表达及调控 PI3K/AKT信号通路的研究[J].现代检验医学杂志,2022,37(01):119.[doi:10.3969/j.issn.1671-7414.2022.01.024]
　LIU Jing-ya,ZHANG Hai-liang,LI Bao-ping,et al.Expression of Long Non-coding RNA SNHG1 in Endometrial Carcinoma and Its Regulation of PI3K/AKT Signaling Pathway[J].Journal of Modern Laboratory Medicine,2022,37(06):119.[doi:10.3969/j.issn.1671-7414.2022.01.024]
[8]彭 浩,张印星,谢 环.长链非编码RNA CDKN2BAS 在子宫内膜癌组织表达及其生物学功能研究[J].现代检验医学杂志,2023,38(03):92.[doi:10.3969/j.issn.1671-7414.2023.03.016]
　PENG Hao,ZHANG Yin-xing,XIE Huan.Expression and Biological Function of Long Non-coding RNA CDKN2BAS in Endometrial Carcinoma[J].Journal of Modern Laboratory Medicine,2023,38(06):92.[doi:10.3969/j.issn.1671-7414.2023.03.016]
[9]梁燕茹,郑 瑜,李 倩.子宫内膜癌患者术前血清apo AI 和Apelin 水平检测对预测淋巴脉管间隙浸润风险的价值研究[J].现代检验医学杂志,2023,38(05):53.[doi:10.3969/j.issn.1671-7414.2023.05.010]
　LIANG Yanru,ZHENG Yu,LI Qian.Value of Preoperative Serum Apo AI and Apelin Levels in Predicting the Risk of Lymph Node Vascular Space Infiltration in Patients with Endometrial Cancer[J].Journal of Modern Laboratory Medicine,2023,38(06):53.[doi:10.3969/j.issn.1671-7414.2023.05.010]
[10]陆 瑞,郭红霞,吴苗苗,等.KIF18B 通过激活Wnt/β catenin 信号通路促进子宫内膜癌细胞增殖和转移的实验研究[J].现代检验医学杂志,2023,38(05):58.[doi:10.3969/j.issn.1671-7414.2023.05.011]
　LU Rui,GUO Hongxia,WU Miaomiao,et al.Experimental Study of KIF18B Promoting Endometrial Cancer Cell Proliferation and Metastasis by Activating Wnt/β-catenin Signaling Pathway[J].Journal of Modern Laboratory Medicine,2023,38(06):58.[doi:10.3969/j.issn.1671-7414.2023.05.011]

备注/Memo

备注/Memo:
基金项目：河北省医学科学研究课题计划（编号：20231755）：免疫检查点PD-1，VISTA 在子宫内膜癌免疫微循环中的表达及意义。
作者简介：柴静（1983-），女，硕士研究生，副主任医师，研究方向：妇科肿瘤，E-mail：s81p3d@163.com。
更新日期/Last Update: 2023-11-15